Abstract:This study addresses the challenges in evaluating botulinum neurotoxin type A (BoNT/A) efficacy and understanding species‐specific responses. By developing a kinetic‐pharmacodynamic (K‐PD) model, it interprets muscle function data from animal studies, offering insights into BoNT/A effects and potential applications in humans. This approach enhances translational relevance and may improve therapeutic outcomes for conditions involving muscle spasticity. Botulinum neurotoxins (BoNTs) are commonly used in therapeutic and cosmetic applications. One such neurotoxin, BoNT type A (BoNT/A), has been studied widely for its effects on muscle function and contraction. Despite the importance of BoNT/A products, determining the blood concentrations of these toxins can be challenging. To address this, researchers have focused on pharmacodynamic (PD) markers, including compound muscle action potential (CMAP) and digit abduction scoring (DAS). In this study, we aimed to develop a probabilistic kinetic‐pharmacodynamic (K‐PD) model to interpret CMAP and DAS data obtained from mice and rats during the development of BoNT/A products. The researchers also wanted to gain a better understanding of how the estimated parameters from the model relate to the bridging of animal models to human responses. We used female Institute of Cancer Research mice and Sprague‐Dawley (SD) rats to measure CMAP and DAS levels over 32 weeks after administering BoNT/A. We developed a muscle‐contraction inhibition model using a virtual pharmacokinetic (PK) compartment combined with an indirect response model and performed model diagnostics using goodness‐of‐fit analysis, visual predictive checks (VPC), and bootstrap analysis. The CMAP and DAS profiles were dose‐dependent, with recovery times varying depending on the administered dose. The final K‐PD model effectively characterized the data and provided insights into species‐specific differences in the PK and PD parameters. Overall, this study demonstrated the utility of PK‐PD modeling in understanding the effects of BoNT/A and provides a foundation for future research on other BoNT/A products.

Dissociation mechanics and stability of type A botulinum neurotoxin complex by means of biophysical evaluation

None Detectable Retrograde Transport Of Chinese Botulinum Toxin Type A In Mice By Single Intramuscular Injection

Intramuscular Botulinum Neurotoxin Serotypes E and A Elicit Distinct Effects on SNAP25 Protein Fragments, Muscular Histology, Spread and Neuronal Transport: An Integrated Histology-Based Study in the Rat

The Behavioural Effects and Sept-Hippocampal Cholinergic Activity Changes Caused by Repeated Bont/A Injection on Facial Muscle in Adolescent Mice

In vitro quantification of botulinum neurotoxin type A1 using immobilized nerve cell-mimicking nanoreactors in a microfluidic platform

Resolution of Two Steps in Botulinum Neurotoxin Serotype A1 Light Chain Localization to the Intracellular Plasma Membrane

Model‐based interspecies interpretation of botulinum neurotoxin type A on muscle‐contraction inhibition

A Novel Catalytically Inactive Construct of Botulinum Neurotoxin A (BoNT/A) Directly Inhibits Visceral Sensory Signalling

Influence of Injection of Chinese Botulinum Toxin Type A on the Histomorphology and Myosin Heavy Chain Composition of Rat Gastrocnemius Muscles.

Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies

Assembly and function of the botulinum neurotoxin progenitor complex

Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C

Investigations of Thiosemicarbazides as Botulinum Toxin Active-Site Inhibitors: Enzyme, Cellular, and Rodent Intoxication Studies

Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2

Crystal Structure of the Catalytic Domain of a Botulinum Neurotoxin Homologue from Enterococcus faecium: Potential Insights into Substrate Recognition

Botulinum Toxin Type B Micromechanosensor

Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity

SiO 2 /Si interferometers designed for on-site botulinum neurotoxin serotypes B and C quantification and biological activity assessment

Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release

Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology

Conformational Space of the Translocation Domain of Botulinum Toxin: Atomistic Modeling and Mesoscopic Description of the Coiled-Coil Helix Bundle